Immunogenicity of yellow fever vaccine co-administered with 13-valent pneumococcal conjugate vaccine in rural Gambia: A cluster-randomised trial
No evidence was found of the non-inferiority of the seroresponse to YF vaccine when co-administered with PCV13. The levels of YF NA attaining seroprotection (NT ≥1:8) were high in all groups. PCV13 co-administered with YF vaccine at 9 months does not affect seroresponse to YF vaccine. http://www.isrctn.org/ - ISRCTN72821613.
Authors
- Golam Sarwar (ORCID: https://orcid.org/0000-0002-3573-8457)
- Paul V. Licciardi (ORCID: https://orcid.org/0000-0001-6086-6285)
- Stéphanie Jansen (ORCID: https://orcid.org/0000-0002-4623-5070)
- Brian Greenwood (ORCID: https://orcid.org/0000-0001-5725-9118)
- Ed Clarke (ORCID: https://orcid.org/0000-0002-7785-0340)
- Umberto D’Alessandro (ORCID: https://orcid.org/0000-0001-6341-5009)
- Nuredin Mohammed (ORCID: https://orcid.org/0000-0002-4067-1103)
- Cattram Nguyen (ORCID: https://orcid.org/0000-0002-0599-8645)
- Grant Mackenzie (ORCID: https://orcid.org/0000-0002-4994-2627)
- Rasheed Salaudeen
- Jonas Schmidt‐Chanasit (ORCID: https://orcid.org/0000-0003-4433-0231)
- Isaac Osei (ORCID: https://orcid.org/0000-0002-9370-9363)
- Ousman Secka (ORCID: https://orcid.org/0000-0002-1410-7023)
Institutions
- University of London (GB)
- Universität Hamburg (DE)
- London School of Hygiene & Tropical Medicine (GB)
- MRC Unit the Gambia (GM)
- Murdoch Children's Research Institute (AU)
- Bernhard Nocht Institute for Tropical Medicine (DE)
Publication Details
- Journal
- Vaccine
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1016/j.vaccine.2025.126712
- Citations
- 1
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- Bill and Melinda Gates Foundation
- Medical Research Council